GHK-Cu Research: Models, Findings and Limits

Scope of this reference

This page describes the shape of the published research on GHK-Cu and the evidence tier of each finding. It is not a treatment guide, a recommendation, a human-use protocol or evidence that the listed material is safe or effective in people or animals.

The shape of the literature

A PubMed search for "GHK-Cu" in titles and abstracts returned 84 records on 28 October 2026. The sources used on this page fall into three groups:

• •Founding laboratory work, 1980 onward. Cell-culture and chemistry papers. The two earliest cited here were co-authored by Loren Pickart, who is also first author of the 2018 review.
• •Reviews. The most-cited reviews come from the same research group, and the authors of the 2018 review give a skin-biology company research and development department as their affiliation. They read as one body of work, not as independent confirmations of each other.
• •Recent animal studies. Mouse studies from academic groups in China, each using an induced-disease model.

There is one item in that set which PubMed classifies as a clinical trial. It is described under human data below. The mechanism is covered on the GHK-Cu mechanism page and the compound itself on the GHK-Cu identity page.

In vitro findings

Every statement in this section describes cells or chemistry, not an organism.

• •Copper uptake. A 1980 paper in Nature reported that the tripeptide forms complexes with copper(II) and enhanced copper uptake into cultured hepatoma cells.
• •Collagen synthesis. A 1988 paper reported that the copper complex stimulated collagen synthesis in fibroblast cultures. The effect began between 10⁻¹² and 10⁻¹¹ M, peaked near 10⁻⁹ M and was independent of any change in cell number.
• •Chemistry. Structural work shows how copper(II) is held by the peptide and that the complex can be reduced to copper(I), releasing the metal, under suitable conditions.
• •Review summaries. Reviews describe changes in glycosaminoglycan synthesis and metalloproteinase activity in cultures. We cite those as the reviews' statements, not as findings we have checked against the primary papers.

A change in a culture dish does not show a change in tissue, and it does not show one in a person.

Animal findings

Three recent studies show the pattern. Each is in mice and each uses a disease-induction model, so the species and model are the whole of what they establish.

Older reviews describe work in other species. We have not reviewed those primary reports for this page and do not summarise them. Findings in one species and one model do not carry across to another.

Human data

Human evidence is thin and none of it concerns a research reagent.

• •A small randomised trial of a topical cosmetic product. A 2006 trial in Archives of Facial Plastic Surgery randomised patients to skin care products with or without GHK-Cu after laser resurfacing of the skin. Thirteen completed it. Computer analysis and blinded evaluators found no statistically significant objective difference between the groups. A patient questionnaire did show higher reported satisfaction with the GHK-Cu product.
• •A measurement of the natural peptide. A 2023 study measured plasma GHK in 9 patients with chronic obstructive pulmonary disease and 11 healthy controls, and found lower levels in the patients. It measured an endogenous peptide. It is evidence about biology, not about a supplied material.
• •Reviews of topical formulations. Reviews describe further small studies of cosmetic products applied to skin. They concern finished cosmetic formulations, not the catalogue item.

What cannot be concluded

• •That the actions are uniformly beneficial. A widely cited 2018 review states that every biological action known for the peptide appears to be health-positive. Its authors work for a skin-biology company, and no independent human study cited on this page supports a statement that broad.
• •That effects in a dish are effects in tissue. Collagen synthesis in fibroblast culture is a measurement of cultured cells.
• •That mouse disease-model results describe people. They describe those mice under those conditions.
• •That "copper peptide" skincare studies describe GHK-Cu as supplied here. Cosmetic ingredient lists use the name copper tripeptide-1 for a formulated product, and the term "copper peptides" also covers other molecules.
• •That a long citation list is independent evidence. The founding work and several reviews share authors.

What would need to be studied

• •Independent replication of the cell findings, with copper-free controls to separate the peptide from the metal.
• •The proposed protein targets confirmed by methods other than docking and expression changes.
• •Properly sized controlled human studies of any single claimed action, with outcomes fixed in advance.

Analytical documentation

What a batch COA for this material reports

The product record lists batch 100238 with an HPLC purity of 99.843%, and the certificate states the GHK-Cu content and the copper fraction separately. The report is in the COA library, and the catalogue record is the GHK-Cu 50mg product page. Related items sit in the copper and skin category, and the GHK-Cu buying guide covers the catalogue side.

What a COA cannot establish

A certificate reports identity and measured composition for the batch tested. It says nothing about biological effect and does not extend to other batches. The guides to reading a peptide COA and understanding HPLC purity explain the limits, and current prices are listed separately.

Key references

• •Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-717. doi:10.1038/288715a0
• •Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. doi:10.1016/0014-5793(88)80509-x
• •Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. doi:10.1001/archfaci.8.4.252
• •Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987
• •Deng M, Zhang Q, Yan L, et al. Glycyl-L-histidyl-L-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway. J Cachexia Sarcopenia Muscle. 2023;14(3):1365-1380. doi:10.1002/jcsm.13213
• •Bian Y, Deng M, Liu J, et al. The glycyl-L-histidyl-L-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biol. 2024;75:103237. doi:10.1016/j.redox.2024.103237
• •Mao S, Huang J, Li J, et al. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Front Pharmacol. 2025;16:1551843. doi:10.3389/fphar.2025.1551843

Laboratory-use boundary

Materials sold on this site are supplied solely for non-clinical in-vitro laboratory research. They must not be ingested, injected, inhaled, applied or otherwise administered to a human or animal.

We do not provide dosing, routes of administration, treatment guidance, cosmetic-use guidance or in-vivo protocols. Preparation, storage and handling must follow a validated institutional SOP, the material documentation and an appropriate risk assessment.